Filing Flows › Altimmune (ALT) › Recalls, complaints & regulation
Altimmune (ALT): clinical trials
Altimmune (ALT) beyond its filings: 2 active clinical trials.
Altimmune's latest quarter
Altimmune, Q4 2025: revenue $26K (+420% year over year), net loss $27.4M, operating cash flow −$19.4M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Altimmune have?
2 active studies on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.